Clinical Trial Update: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 clinical trial of CT0596 for relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• CT0596

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | EARLY_Phase 1 | Status: RECRUITING